Valuation: Cogent Biosciences, Inc.

Market Cap 6.29B 5.39B 5.04B 4.61B 8.7B 602B 8.79B 59.66B 23.2B 302B 23.61B 23.1B 1,000B P/E 2026 *
-16.1x
P/E 2027 * -34.6x
Enterprise Value 5.89B 5.04B 4.72B 4.31B 8.14B 564B 8.23B 55.84B 21.71B 283B 22.1B 21.62B 936B EV / Sales 2026 *
983x
EV / Sales 2027 * 21.3x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 day-1.36%
1 week-4.33%
Current month-6.94%
1 month-8.88%
3 months+10.90%
6 months-7.53%
Current year+2.00%
1 week 34.91
Extreme 34.91
38.62
1 month 34.91
Extreme 34.91
43.39
Current year 30.87
Extreme 30.87
43.39
1 year 11.6
Extreme 11.6
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 2020-10-22
Director of Finance/CFO 45 2018-05-31
Chief Tech/Sci/R&D Officer 52 2021-04-05
Director TitleAgeSince
Director/Board Member 68 2018-01-31
Director/Board Member 74 2019-07-25
Director/Board Member 59 2019-07-25
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Free

Director

627 0.0004%
6/9/26 Free

Director

17,901 0.0105%
6/9/26 Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
-1.36%-4.33%+198.93%+200.66% 6.38B
-4.31%-6.62%+65.79%+98.02% 72.12B
-4.19%+1.05%+52.79%+85.53% 65.85B
-3.22%+23.17%+1.75%-5.23% 29.28B
-1.42%-3.38%-5.99%+465.34% 27.47B
+4.12%+4.26%+52.19%+14.21% 26.7B
-1.81%+0.38%+34.52%-18.33% 20.06B
+5.36%+4.61%+270.18%+415.10% 18.22B
-0.19%-3.87%+11.00%+516.79% 16.4B
+0.87%+4.26%+41.21%+150.80% 13.4B
Average -0.62%+4.39%+72.24%+192.29% 29.59B
Weighted average by Cap. -1.85%+2.97%+57.85%+151.01%

Financials

2026 *2027 *
Net sales 5.99M 5.13M 4.8M 4.39M 8.28M 573M 8.37M 56.81M 22.09M 288M 22.49M 22M 953M 292M 250M 234M 214M 404M 27.95B 408M 2.77B 1.08B 14.03B 1.1B 1.07B 46.43B
Net income -405M -347M -325M -297M -561M -38.81B -567M -3.85B -1.5B -19.49B -1.52B -1.49B -64.48B -199M -170M -159M -146M -275M -19.04B -278M -1.89B -733M -9.56B -746M -730M -31.63B
Net Debt -403M -345M -323M -295M -557M -38.55B -563M -3.82B -1.49B -19.36B -1.51B -1.48B -64.05B -77.95M -66.81M -62.5M -57.14M -108M -7.46B -109M -740M -288M -3.75B -293M -286M -12.4B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
26-08-24 US$36.23 -1.36% 1,214,544
26-08-21 US$36.73 +4.02% 2,515,752
26-08-20 US$35.31 -4.18% 1,943,841
26-08-19 US$36.85 -1.47% 1,249,799
26-08-18 US$37.40 -1.24% 1,151,059
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
36.23USD
Average target price
55.82USD
Spread / Average Target
+54.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock